Mexico proposes matching US tariffs on China, Bessent suggests Canada follows suit

Stuttgart - Delayed Quote EUR

Altimmune Inc (3G0.SG)

6.02

-0.24

(-3.87%)

At close: 8:18:01 AM GMT+1

No Tool

Measure

UNDO

Redo

All

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for 3G0.SG

Altimmune Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line

Altimmune Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line

Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors

Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors

Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025

Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025

With 56% institutional ownership, Altimmune, Inc. (NASDAQ:ALT) is a favorite amongst the big guns

With 56% institutional ownership, Altimmune, Inc. (NASDAQ:ALT) is a favorite amongst the big guns

Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference

Altimmune to Participate in the Guggenheim SMID Cap Biotech Conference

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate

Altimmune Added to Nasdaq Biotechnology Index

Altimmune Added to Nasdaq Biotechnology Index

Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders

Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders

Altimmune to Participate at Two Upcoming Investor Conferences

Altimmune to Participate at Two Upcoming Investor Conferences

Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024

Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024